# Tonix Pharmaceuticals, Inc. clinical trials: 34 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 34 trials with Tonix Pharmaceuticals, Inc. as lead sponsor, 1 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Tonix Pharmaceuticals, Inc.: 34 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/tonix-pharmaceuticals-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 34
- Recruiting or not yet: 1
- Read on: November 19, 2026

## Trials

The 25 newest of 34, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| June 2, 2026 | NCT07621237 | A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD) | Tonix Pharmaceuticals, Inc. | Phase 2 | Recruiting | Major Depressive Episode (MDE), Major Depressive Disorder (MDD), Depression | 360 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07621237) |
| March 16, 2026 | NCT07473752 | A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Escalation Study to Evaluate the Safety, Tolerability... | Tonix Pharmaceuticals, Inc. | Phase 1 | Completed | Phase 1 First-in-human Study Involving Healthy Subjects | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07473752) |
| March 11, 2026 | NCT07464535 | A Single-Dose, Randomized, Open-Label, 2-Way Crossover Study to Evaluate the Dose-Proportionality, Safety, and Tolerability of TNX-102 SL... | Tonix Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy Subjects (HS) | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07464535) |
| February 17, 2026 | NCT07413367 | A Phase 1, Open-Label, Parallel-Group, Single-Dose Study To Compare The Pharmakokinetics Of TNX-102 SL (Cyclobenzaprine Hydrochloride... | Tonix Pharmaceuticals, Inc. | Phase 1 | Active not recruiting | Pharmakokinetic, Open Label, Phase 1 | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07413367) |
| September 21, 2023 | NCT06045793 | Comparing Efficacy & Safety Of TNX-1300 To Placebo With UC For Treatment Of Acute Cocaine Intoxication In ED Subjects (CATALYST) | Tonix Pharmaceuticals, Inc. | Phase 2 | Terminated | Cocaine Use, Cocaine Intoxication, Cocaine Toxicity, Cocaine Abuse, Cocaine Adverse Reaction | 3 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06045793) |
| January 17, 2023 | NCT05686408 | Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD) | Tonix Pharmaceuticals, Inc. | Phase 2 | Completed | Depression, Depressive Disorder, Depressive Symptoms, Depressive Disorder, Major, Depressive Episode, Depression Severe | 132 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05686408) |
| January 11, 2023 | NCT05679908 | A Study to Evaluate the Efficacy and Safety of TNX-1900 in Patients With Chronic Migraine | Tonix Pharmaceuticals, Inc. | Phase 2 | Completed | Chronic Migraine, Chronic Migraine, Headache, Chronic Migraine Without Aura, Aura Migraine | 88 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05679908) |
| July 25, 2022 | NCT05472090 | A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of... | Tonix Pharmaceuticals, Inc. | Phase 2 | Completed | Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection, COVID-19, Long COVID, Long Haul COVID | 63 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05472090) |
| May 13, 2022 | NCT05372887 | Safety and Efficacy Study of TNX-102 SL in Participants With PTSD | Tonix Pharmaceuticals, Inc. | Phase 2 | Withdrawn | PTSD | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05372887) |
| March 10, 2022 | NCT05273749 | A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With Fibromyalgia | Tonix Pharmaceuticals, Inc. | Phase 3 | Completed | Fibromyalgia | 457 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05273749) |
| January 31, 2022 | NCT05216510 | Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide Antigens | Tonix Pharmaceuticals, Inc. | Phase 1 | Terminated | Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2 | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05216510) |
| August 9, 2021 | NCT04996056 | An Open-Label, Randomized Pilot Study Comparing the Safety of a Single Dose of TNX-1300 to Usual Care (UC) Alone for the Treatment of Signs... | Tonix Pharmaceuticals, Inc. | Phase 2 | Withdrawn | Cocaine Intoxication | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04996056) |
| August 11, 2020 | NCT04508621 | A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia | Tonix Pharmaceuticals, Inc. | Phase 3 | Completed | Fibromyalgia | 514 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04508621) |
| November 21, 2019 | NCT04172831 | A Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia | Tonix Pharmaceuticals, Inc. | Phase 3 | Completed | Fibromyalgia | 503 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04172831) |
| November 15, 2019 | NCT04164719 | Dose-Proportionality and Food Effect Study of TNX-102 SL | Tonix Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy Subjects | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04164719) |
| February 15, 2019 | NCT03841773 | A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD | Tonix Pharmaceuticals, Inc. | Phase 3 | Terminated | PTSD | 192 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03841773) |
| April 26, 2018 | NCT03508700 | A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD | Tonix Pharmaceuticals, Inc. | Phase 3 | Completed | PTSD | 93 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03508700) |
| February 23, 2018 | NCT03443960 | Steady-State Pharmacokinetic Comparison Study of TNX-102 SL 5.6 mg Versus AMRIX® 30 mg ER Capsules | Tonix Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy Subjects | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03443960) |
| May 30, 2017 | NCT03168022 | Bioequivalence Study of TNX-102 SL 2.8 mg Sublingual Tablets From Two Manufacturers. | Tonix Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy Adults | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03168022) |
| April 12, 2017 | NCT03110575 | 12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients | Tonix Pharmaceuticals, Inc. | Phase 3 | Terminated | PTSD | 190 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03110575) |
| February 23, 2017 | NCT03062540 | Safety and Efficacy Study of TNX-102 SL in Patients With Military-related PTSD | Tonix Pharmaceuticals, Inc. | Phase 3 | Terminated | PTSD | 358 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03062540) |
| July 12, 2016 | NCT02829814 | Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia | Tonix Pharmaceuticals, Inc. | Phase 3 | Terminated | Fibromyalgia, Myofascial Pain Syndromes, Muscular Diseases, Nervous System Diseases, Neuromuscular Diseases, Rheumatic... | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02829814) |
| October 28, 2015 | NCT02589275 | A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients | Tonix Pharmaceuticals, Inc. | Phase 3 | Completed | Primary Fibromyalgia | 375 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02589275) |
| May 6, 2015 | NCT02436096 | A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia | Tonix Pharmaceuticals, Inc. | Phase 3 | Completed | Fibromyalgia, Myofascial Pain Syndromes, Muscular Diseases, Musculoskeletal Diseases, Nervous System Diseases... | 519 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02436096) |
| April 22, 2015 | NCT02423408 | Safety and Efficacy Study of TNX-201 Capsules for Treatment of Single Tension-Type Headache | Tonix Pharmaceuticals, Inc. | Phase 2 | Completed | Tension-Type Headache | 165 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02423408) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 12 |
| Phase 2 | 10 |
| Phase 2/3 | 1 |
| Phase 3 | 11 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 24 |
| Terminated | 6 |
| Withdrawn | 2 |
| Recruiting | 1 |
| Active not recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Fibromyalgia | 8 |
| Stress Disorders, Post-Traumatic | 7 |
| Pain | 6 |
| Depressive Disorder, Major | 2 |
| Depression | 2 |
| Myofascial Pain Syndromes | 2 |
| Muscular Diseases | 2 |
| Nervous System Diseases | 2 |
| Neuromuscular Diseases | 2 |
| Rheumatic Diseases | 2 |
| Musculoskeletal Diseases | 2 |
| Cocaine-Related Disorders | 1 |
| Emergencies | 1 |
| Tension-Type Headache | 1 |
| Infections | 1 |
| COVID-19 | 1 |
| Post-Acute COVID-19 Syndrome | 1 |
| Parasomnias | 1 |
| Coronavirus Infections | 1 |
| Headache | 1 |
| Migraine with Aura | 1 |
| Migraine Disorders | 1 |
| Depressive Disorder | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Playground equipment suppliers in the United States](https://specstream.ai/data/businesses/playground-equipment-suppliers/united-states)
- [Hazardous waste disposal companies in the United States](https://specstream.ai/data/businesses/hazardous-waste-disposal-companies/united-states)
- [Cabinet makers in the United States](https://specstream.ai/data/businesses/cabinet-makers/united-states)
- [Test preparation centers in the United States](https://specstream.ai/data/businesses/test-preparation-centers/united-states)
- [Montessori schools in the United States](https://specstream.ai/data/businesses/montessori-schools/united-states)
